ASP Isotopes (ASPI) investor relations material

Strategic vision and market positioning

• Focused on scaling isotope enrichment capacity, expanding product portfolio, and optimizing unit economics to address critical supply chain vulnerabilities in electronics, nuclear medicine, and nuclear energy markets.

• Operates three isotope enrichment facilities in South Africa, with plans for additional sites in Iceland, UK, and USA.

• Strategic partnerships and customer agreements in place for high-value end markets, including semiconductors and radiopharmaceuticals.

• Targeting multi-billion dollar opportunities in electronics, nuclear medicine, and advanced nuclear fuels.

Technology and product development

• Utilizes Aerodynamic Separation Process (ASP) for lighter gases and Quantum Enrichment (QE) for heavier metals, enabling scalable and cost-effective isotope production.

• Key products include enriched Silicon-28, Carbon-14, and Ytterbium-176, with applications in quantum computing, semiconductors, and cancer treatment.

• Proprietary methods for manufacturing fluorinated gases and helium, critical for semiconductor manufacturing.

• Plans to supply enriched uranium and lithium for advanced nuclear reactors, pending regulatory approvals.

Operational milestones and financial outlook

• First commercial shipments of Si-28, C-14, and Yb-176 expected in Q3 2026; helium production at nameplate capacity also targeted for Q3 2026.

• Radiopharmacy operations expanding, with multiple drug candidates advancing toward Phase 1 clinical trials in 2026.

• EBITDA target of over $300 million by 2031, with segment contributions from electronic gases, medical isotopes, radiopharmaceuticals, and LNG.

• Reported $5.7M in total revenue for Q1 2026, with $290.5M in cash and short-term investments as of March 31, 2026.